Clinical trials: Cyclophosphamide, completed
Inflammatory Breast Cancer, Male Breast Cancer
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
This phase II trial studies how well giving sunitinib malate together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00513695
- Testing
- sunitinib malate, paclitaxel, doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Washington
Triple Negative Breast Cancer
Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)
Previous studies in Western country show that triple-negative breast cancer has aggressive clinical and pathological features compared with non-triple negative breast cancer, including onset at a young age, advanced clinical…
- Trial name
- NCT01216111
- Testing
- Paclitaxel Cisplatin, fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
- Volunteers
- 647 people
- Sponsor
- Fudan University
MDS, Leukemias
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
The purpose of this study is to see if giving high dose chemotherapy and total body irradiation before and repeating high dose chemotherapy after a bone marrow transplant could reduce the incidence of graft rejection and disease…
- Conditions
- MDS, Leukemias, Lymphomas
- Trial name
- NCT00796562
- Testing
- Busulfan, Cyclophosphamide, Total body irradiation
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Funding Source - FDA OOPD FDR004128 The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8.
- Trial name
- NCT00877110
- Testing
- cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Sclerosis
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
Multiple Sclerosis is a disease that may be caused by the immune system reacting against the nervous system. It is possible, that by changing the immune system we can modify the progression of this disease.
- Trial name
- NCT00040482
- Testing
- Cyclophosphamide, ATG, MESNA
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Sarcoma
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00742924
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 88 sites in United States, Australia and 2 more
- Volunteers
- 24 people
- Sponsor
- Children's Oncology Group
Metastatic Ovarian Cancer
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma.
- Trial name
- NCT03287674
- Testing
- Cyclophosphamide, Fludarabine, TIL infusion
- Where
- Denmark
- Volunteers
- 7 people
- Sponsor
- Inge Marie Svane
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory).
- Trial name
- NCT01415882
- Testing
- Cyclophosphamide, Daratumumab, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01093586
- Testing
- double-unit umbilical cord blood transplantation, cytogenetic analysis, bone marrow aspiration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Hodgkin's Lymphoma
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months.
- Trial name
- NCT00610883
- Testing
- LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 positive (CD20+) DLBCL or FL.
- Trial name
- NCT01889069
- Testing
- Rituximab, Cyclophosphamide, Vincristine
- Where
- 39 sites in Italy
- Volunteers
- 159 people
- Sponsor
- Hoffmann-La Roche
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia…
- Trial name
- NCT00408005
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 215 sites in United States, Australia and 3 more
- Volunteers
- 1,895 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00941720
- Testing
- busulfan, cyclophosphamide, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Case Comprehensive Cancer Center
Refractory Acute Myeloid Leukemia
Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in acute myeloid leukemia (AML) or refractory multiple relapses after chemotherapy.
- Trial name
- SET-HAPLO (NCT03035422)
- Testing
- Sequential Packaging (SET), Transfusion graft, Prevention of GVHD
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Extraocular Retinoblastoma
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
This phase III trial is studying the side effects and how well giving combination chemotherapy together with autologous stem cell transplant and/or radiation therapy works in treating young patients with extraocular…
- Trial name
- NCT00554788
- Testing
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin
- Where
- 73 sites in United States, Argentina and 4 more
- Volunteers
- 60 people
- Sponsor
- Children's Oncology Group
Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor
This phase III trial is studying how well combination chemotherapy followed by second-look surgery and radiation therapy works in treating children with nonmetastatic medulloblastoma or primitive neuroectodermal tumor.
- Trial name
- NCT00006461
- Testing
- cisplatin, cyclophosphamide, vincristine sulfate
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Children's Oncology Group
Chronic Lymphocytic Leukemia
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00281983
- Testing
- alemtuzumab, anti-thymocyte globulin, filgrastim
- Where
- 13 sites in Canada, Germany
- Volunteers
- 100 people
- Sponsor
- German CLL Study Group
Colorectal Cancer, Metastatic Cancer
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an…
- Trial name
- NCT00656123
- Testing
- Colon GVAX, cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma, Diffuse Large Cell
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma
The purpose of this study is to determine whether people have genes that make them more likely to respond to chemotherapy and/or have side effects from chemotherapy for diffuse large cell lymphoma.
- Trial name
- NCT00590941
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.